Article Figures & Data
Figures
- Figure 1.
Radiologic images and disease course. A to E, cerebral MRI. White circles, brain metastasis. F to N, thoracic CT scan. Red circles, right paratracheal lymphadenopathies (I and L), right (J and M), and left hilar lymphadenopathies (K and N). F, G, and H, no lymphadenopathies. O to P, whole body PET-CT scan. Black arrows, left axillary lymphadenopathy and left anterior chest wall nodule. Bottom, timeline showing therapy and disease status. Sentinel lymph node procedure (Sent. LN). Lymph node metastasis surgery 1 (LN1), right iliac obdurator and inguinal radical lymph node dissection. LN2, right and left pelvic lymph node dissection. LN3, left axillary lymph node dissection + mediastinoscopy + left anterior chest wall nodule resection. Subcutaneous melanoma metastasis resection 1 (Subcut. MM1), right parapubic subcutaneous nodule resection. Subcut. MM2, right subpubic subcutaneous nodule resection. Subcut. MM3, right inguinal subcutaneous nodule resection. Sarcoid-like granulomatosis (Sarc-.LG). SB-AS2: i.d. vaccines 1, 3, and 5 of Melan-A + MAGE-A10; i.m. vaccines 2, 4 and 6 of Melan-A + MAGE-A10 + SB-AS2. ISA-51: s.c vaccines of Melan-A + MAGE-A10 + NY-ESO-1 + Montanide. ISA-51 + CpG, s.c. vaccines of Melan-A + MAGE-A10 + NY-ESO-1 + Montanide+ CpG. CpG, s.c. vaccines of Melan-A + MAGE-A10 + NY-ESO-1 + CpG; MM, melanoma metastasis; NED, no evidence of disease. PD, progressive disease; vertical arrows, surgeries; irradiation symbol + vertical arrow, radiosurgery.
- Figure 2.
Immunohistochemical analysis of immune cells in paraffin-embedded right paratracheal lymph nodes. A, CD68+ macrophages. B, CD4+ T lymphocytes. C, CD8+ T lymphocytes. D, CD45RO+ lymphocytes. E, FoxP3+ lymphocytes. F, CD25+ lymphocytes. All images were taken from the same tissue section. IHC with isotype control antibodies were negative (not shown).
- Figure 3.
T-cell responses. A, representative example dot plots from PBMCs, showing Melan-A–specific cells (left), of NY-ESO-1–specific cells (middle), and MAGE-A10–specific cells (right) among CD8+ T cells. B, percentages of CD3+, CD4+, and CD8+ T cells in PBMCs. C, direct ex vivo ELISPOT analysis of total PBMCs, IFNγ production after 24 hours incubation with specific peptides (Melan-A, NY-ESO-1, and MAGE-A10). Ex vivo tetramer analysis of Melan-A– (D), NY-ESO-1– (F), and MAGE-A10 (H)–specific CD8+ T cells after the different vaccinations. Percentages of CD28− cells among the Melan-A–specific (E), NY-ESO-1–specific (G), and MAGE-A10–specific (I) CD8+ T cells.
Volume 2, Issue 12
